CAR T-cell Therapy
TIL Therapy for Cancer
This trial tests a treatment using a patient's own immune cells to fight various cancers that haven't responded to other treatments or have come back. The immune cells are taken from the tumor, grown in a lab, and then reintroduced into the body to target and kill cancer cells. The study aims to see how well this approach works and how safe it is.
MDM2 Inhibitor
Navtemadlin + Radiation for Soft Tissue Sarcoma
This trial studies the effects of navtemadlin and radiation therapy in patients with soft tissue sarcoma. Navtemadlin helps stop cancer cells from growing, and radiation therapy kills them with high-energy x-rays. The goal is to shrink the tumor before surgery to remove less normal tissue. Navtemadlin is a newer drug being tested for its ability to stop cancer cells from growing.
PD-1 Inhibitor
Pembrolizumab + Radiotherapy for Soft Tissue Sarcoma
This trial is comparing two different treatments for cancer. One treatment is standard radiotherapy followed by surgery. The other treatment is a new immunotherapy drug called pembrolizumab, given before and after radiotherapy and surgery.
Popular Filters
Trials for STS Patients
Monoclonal Antibodies
Retifanlimab + Chemotherapy for Soft Tissue Sarcoma
This trial is testing a new drug, Retifanlimab, to see if it is safe and effective when combined with two existing chemotherapy drugs, gemcitabine and docetaxel, to treat patients with soft tissue sarcoma.
Alkylating agents
Chemotherapy + Radiation for Soft Tissue Sarcoma
This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.
Trials for Rhabdomyosarcoma Patients
Monoclonal Antibodies
Retifanlimab + Chemotherapy for Soft Tissue Sarcoma
This trial is testing a new drug, Retifanlimab, to see if it is safe and effective when combined with two existing chemotherapy drugs, gemcitabine and docetaxel, to treat patients with soft tissue sarcoma.
Trials for Metastatic Patients
Monoclonal Antibodies
Retifanlimab + Chemotherapy for Soft Tissue Sarcoma
This trial is testing a new drug, Retifanlimab, to see if it is safe and effective when combined with two existing chemotherapy drugs, gemcitabine and docetaxel, to treat patients with soft tissue sarcoma.
Alkylating agents
Chemotherapy + Radiation for Soft Tissue Sarcoma
This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.
Hyperbaric Oxygen Therapy for Sarcoma
This trial is testing if breathing pure oxygen in a pressurized room can help patients with leg sarcoma heal better after surgery and radiation. The extra oxygen might speed up their recovery. Hyperbaric oxygen therapy (HBOT) has been shown to have beneficial effects in the treatment of late radiation sequelae.
Phase 3 Trials
Alkylating agents
Chemotherapy + Radiation for Soft Tissue Sarcoma
This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.
Radiation Therapy
IMRT for Soft Tissue Sarcoma
This trial will compare the short-term wound healing complications of patients with extremity or truncal soft tissue sarcoma who receive preoperative image guided radiation therapy (IGRT) delivered using intensity modulated radiation therapy (IMRT) to those who receive surgery followed by postoperative IGRT.
Trials With No Placebo
Alkylating agent
Lurbinectedin for Ewing Sarcoma
This trial is testing a medication called lurbinectedin in children and young adults who have already been treated for solid tumors or have a type of cancer called Ewing sarcoma that has come back or didn't respond to other treatments. The medication aims to stop cancer cells from growing and spreading. The study will check if the treatment is safe and effective.
Monoclonal Antibodies
Retifanlimab + Chemotherapy for Soft Tissue Sarcoma
This trial is testing a new drug, Retifanlimab, to see if it is safe and effective when combined with two existing chemotherapy drugs, gemcitabine and docetaxel, to treat patients with soft tissue sarcoma.
Procedure
Intratumoral Microdosing for Cancer
This trial uses a device to inject small amounts of cancer drugs directly into tumors of patients undergoing surgery. The device marks where each drug is injected, allowing researchers to see how different parts of the tumor respond. This helps test cancer drugs early without causing widespread side effects. The device has been shown to induce strong, easily tracked, drug-specific responses in tumors while avoiding toxicity, setting the stage for its application in clinical trials.
View More Related Trials
Frequently Asked Questions
Introduction to soft tissue sarcoma
What are the top hospitals conducting soft tissue sarcoma research?
In the realm of soft tissue sarcoma, several top hospitals are actively engaged in groundbreaking clinical trials. At Memorial Sloan Kettering Cancer Center in New york City, researchers are spearheading eight ongoing trials focused on this complex condition. While they may have conducted only two previous studies so far, their commitment to advancing knowledge and treatment is evident since recording their first ever soft tissue sarcoma trial in 2018. In Saint Louis, both Washington University School of Medicine and Washington University play integral roles as well. The former currently hosts six active clinical trials for soft tissue sarcoma with no prior completed investigations to date. Similarly, at the latter institution, five ongoing trials are dedicated to understanding and combating this rare cancer type without any past recorded studies.
Moving southward to Tampa's Moffitt Cancer Center unveils another center that prioritizes research in soft tissue sarcomas. With a considerable number of five active clinical trials underway presently but no historical records available yet, they contribute significantly towards uncovering new insights into these challenging tumors.
Finally making our way back up north again towards Boston's medical landscape we find Dana-Farber Cancer Institute playing a vital role by conducting four current clinical experiments; although unrecorded history can be traced indicating it being void of previously held investigation measures.
These leading hospitals represent not only centers of excellence but also symbols of hope for individuals battling soft tissue sarcomas worldwide. Through pioneering research and patient-centric approaches fostered within these institutions' premises comes the potential for improved outcomes and a brighter future for all those affected by this complex disease
Which are the best cities for soft tissue sarcoma clinical trials?
When it comes to soft tissue sarcoma clinical trials, several cities have emerged as leaders in research and development. New york, Saint Louis, Boston, Los Angeles, and Philadelphia are at the forefront with multiple ongoing studies focused on different treatments like paclitaxel, olaratumab, ramucirumab, pembrolizumab, and more. These cities provide individuals with access to cutting-edge clinical trials that explore various approaches for treating soft tissue sarcoma. With their commitment to advancing medical knowledge and improving patient outcomes, these cities offer promising opportunities for those affected by this condition.
Which are the top treatments for soft tissue sarcoma being explored in clinical trials?
Soft tissue sarcoma research is making significant strides in clinical trials, with a number of promising treatments at the forefront. Among these top contenders are:
- Pazopanib: Demonstrating potential in soft tissue sarcoma, pazopanib is currently being explored in multiple ongoing clinical trials.
- Trabectedin: Also showing promise, trabectedin has garnered attention in several active trials focused on soft tissue sarcoma.
- Olaratumab: Another treatment under investigation for its efficacy against soft tissue sarcoma, olaratumab is actively being studied to determine its effectiveness. These innovative therapies hold immense hope for patients battling this challenging cancer type as researchers continue to uncover new avenues for treatment.
What are the most recent clinical trials for soft tissue sarcoma?
Recent clinical trials for soft tissue sarcoma offer promising avenues for treatment and improved outcomes. One notable study involves the use of lurbinectedin, ipilimumab, and nivolumab in advanced soft tissue sarcoma patients. This combination therapy shows potential in effectively combating this challenging disease. Another trial focuses on dose selection to optimize treatment efficacy. Furthermore, a single-arm open-label study explores alternative approaches that may benefit patients with soft tissue sarcomas. Additionally, the investigation into niraparib as a therapeutic option demonstrates encouraging results. Lastly, intensity-modulated radiation therapy (IMRT) is being evaluated as an effective treatment modality for soft tissue sarcoma patients seeking better therapeutic options. These diverse studies represent significant advancements in the quest to improve outcomes for individuals battling soft tissue sarcomas
What soft tissue sarcoma clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the field of soft tissue sarcoma research. These trials focused on investigating novel treatments to combat this challenging cancer. A notable trial sponsored by Memorial Sloan Kettering Cancer Center was concluded, bringing us closer to understanding the potential benefits of targeted therapies for soft tissue sarcoma patients. By harnessing the power of precision medicine, researchers are working tirelessly to improve outcomes and offer hope to individuals affected by this complex disease.